{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:22:58Z","timestamp":1793499778026,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ymgme.2025.109284","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:42:22Z","timestamp":1762209742000},"page":"109284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical characteristics and real-world outcomes in patients with mucopolysaccharidosis II over 18\u00a0years: final report of the Hunter Outcome Survey"],"prefix":"10.1016","volume":"146","author":[{"given":"Joseph","family":"Muenzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaco","family":"Botha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Amartino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Harmatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kampmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuan-Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Molter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Raiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tylki-Szyma\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.H.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara K.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2025.109284_bb0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109284_bb0010","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgme.2025.109284_bb0015","unstructured":"EMA, Elaprase Summary of Product Characteristics, 2025 Accessed from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elaprase-epar-product-information_en.pdf. Date Accessed: 28 October 2024."},{"key":"10.1016\/j.ymgme.2025.109284_bb0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D'Avanzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109284_bb0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109284_bb0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","article-title":"Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England","volume":"129","author":"Broomfield","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109284_bb0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2021.03.002","article-title":"The natural history of neurocognition in MPS disorders: a review","volume":"133","author":"Shapiro","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109284_bb0040","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/jmg.19.6.408","article-title":"A clinical and genetic study of Hunter\u2019s syndrome. 2. Differences between the mild and severe forms","volume":"19","author":"Young","year":"1982","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2025.109284_bb0045","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00431-012-1703-y","article-title":"Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls","volume":"171","author":"Burton","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109284_bb0050","article-title":"Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: an analysis from the Hunter Outcome Survey","volume":"37","author":"Lau","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109284_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2021.108392","article-title":"A molecular genetics view on mucopolysaccharidosis type II","volume":"788","author":"Verma","year":"2021","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"10.1016\/j.ymgme.2025.109284_bb0060","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13023-022-02517-0","article-title":"Rare lysosomal disease registries: lessons learned over three decades of real-world evidence","volume":"17","author":"Mistry","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109284_bb0065","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/GIM.0b013e3181f6e74d","article-title":"Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey","volume":"12","author":"Mendelsohn","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109284_bb0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.a.38551","article-title":"Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)","volume":"176","author":"Ficicioglu","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2025.109284_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108576","article-title":"Genotype\u2013phenotype findings in patients with mucopolysaccharidosis II from the Hunter Outcome Survey","volume":"143","author":"Muenzer","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109284_bb0080","first-page":"17","article-title":"Characterization of orthopedic manifestations in patients with mucopolysaccharidosis II using data from 15years of the Hunter Outcome Survey","volume":"65","author":"Link","year":"2024","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2025.109284_bb0085","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jpeds.2011.01.054","article-title":"Prevalence and characterization of cardiac involvement in Hunter syndrome","volume":"159","author":"Kampmann","year":"2011","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109284_bb0090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10545-011-9378-5","article-title":"Hearing loss in patients with mucopolysaccharidosis II: data from HOS \u2013 the Hunter Outcome Survey","volume":"35","author":"Keilmann","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109284_bb0095","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s13023-021-02052-4","article-title":"Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)","volume":"16","author":"Muenzer","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109284_bb0100","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","article-title":"Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)","volume":"40","author":"Burton","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109284_bb0105","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","article-title":"Mortality and cause of death in mucopolysaccharidosis type II\u2014a historical review based on data from the Hunter Outcome Survey (HOS)","volume":"32","author":"Jones","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109284_bb0110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13023-024-03464-8","article-title":"Unmet needs of adults living with mucopolysaccharidosis II: data from the Hunter Outcome Survey","volume":"20","author":"Muenzer","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109284_bb0115","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","article-title":"Initial report from the Hunter Outcome Survey","volume":"10","author":"Wraith","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109284_bb0120","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/21678707.2017.1296761","article-title":"Presentation and treatments for mucopolysaccharidosis type II (MPS II; Hunter syndrome)","volume":"5","author":"Stapleton","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109284_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12808","article-title":"Natural history of valve disease in patients with mucopolysaccharidosis II and the impact of enzyme replacement therapy","volume":"48","author":"Kampmann","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109284_bb0130","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ymgme.2016.01.009","article-title":"The natural history of growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS)","volume":"117","author":"Parini","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109284_bb0135","first-page":"5","article-title":"Growth charts for patients with Hunter syndrome","volume":"1","author":"Patel","year":"2014","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109284_bb0140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109284_bb0145","article-title":"Transition of patients with mucopolysaccharidosis from paediatric to adult care","volume":"21","author":"Lampe","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109284_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-015-0259-0","article-title":"Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study","volume":"10","author":"Guffon","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109284_bb0155","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-015-0265-2","article-title":"Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)","volume":"10","author":"Pano","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109284_bb0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","article-title":"Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS)","volume":"103","author":"Burton","year":"2011","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225002768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225002768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:57:25Z","timestamp":1773871045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719225002768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1096719225002768"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109284","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and real-world outcomes in patients with mucopolysaccharidosis II over 18\u00a0years: final report of the Hunter Outcome Survey","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Takeda Development Centre Americas Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109284"}}